Agency / Source: ZOLL Medical Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA - Continuously Protects Patients from Cardiac Arrest in the Hospital - ZOLL.com
ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA

 

PRZOOM - /newswire/ - Chelmsford, MA, United States, 2017/03/09 - Continuously Protects Patients from Cardiac Arrest in the Hospital - ZOLL.com. NASDAQ: ZOLL

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) to market and begin U.S. distribution of the device.

The ZOLL HWD is specifically designed to continuously protect patients at risk of ventricular tachycardia or ventricular fibrillation (VT/VF) during their stay in the hospital. For a patient experiencing VT/VF, each minute that defibrillation is delayed increases the likelihood of dying or the likelihood of surviving with complications.1

Through automatic detection and immediate treatment, the ZOLL HWD provides patients at risk for VT/VF with continuous protection anytime day or night in the hospital. The HWD is an innovative tool for hospital care teams to manage patients at risk of VT/VF. Automatic detection and immediate treatment address the most critical factor for survival from cardiac arrest in these patients timely defibrillation.

“The HWD offers hospital care teams a new option for managing patients at risk of VT/VF by providing continuous protection even outside of very expensive, high-acuity care areas,” said Jonathan A. Rennert, CEO of ZOLL. “It complements the tool kit the care team has in place for responding to cardiac arrest.”

“The ability to provide hospitalized patients at risk for malignant ventricular arrhythmias a safe and effective device that enables rapid defibrillation represents a significant improvement in the care of cardiovascular patients,” said David M. Shavelle, MD, Associate Clinical Professor at Keck School of Medicine Division of Cardiology at the University of Southern California (USC), Director of Los Angeles County (LAC) USC Cardiac Catheterization Laboratory, and Director of General Cardiology Fellowship Program at USC.
Automatic Detection, Immediate Treatment

The HWD helps the care team manage at-risk patients by detecting VT and VF. If a life-threatening rhythm is detected, the device alerts the patient prior to delivering a treatment shock, and thus allows a conscious patient to delay the treatment shock. The device is designed to deliver treatment within 60 seconds.

The HWD utilizes the same detection algorithm and defibrillation waveform as the LifeVest® Wearable Defibrillator. Patients wearing the LifeVest have a 98% first shock success rate2,3,4 and 92% event survival rate.5,6

About ZOLL Medical Corporation

ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.

About Asahi Kasei

The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by Asahi Kasei Corp., with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

1. Larsen MP, et al. Ann Emerg Med. 1993;22: 1652 58.
2. Chung MK, et al. J Am Coll Cardiol. 2010;56(3):194 203.
3. Klein HU, et al. Pacing Clin Electrophysiol. 2010;33:353 367.
4. Kutyifa V, et al. Circulation. 2015;132(17):1613 1619.
5. Epstein AE, et al. J Am Coll Cardiol. 2013;62(21):2000 2007.
6. Waessnig N, et al. Circulation. 2016;134:635 643.

Copyright © 2017 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: ZOLL Medical Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Diane Egan - ZOLL.com 
978-421-9637 degan[.]zoll.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ZOLL Medical Corporation securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From ZOLL Medical Corporation / Company Profile


Read Medical Services / Equipment Most Recent Related Press Releases:

LigoLab Applauded by Frost & Sullivan for Transforming Diagnostic Laboratories with its All-in-One Integrated LIS & RCM Platform
Withings Acquires Impeto Medical to Strengthen and Grow its Research and Development of Medical Technologies
BostonGene and NEC Announce Global Partnership
Bruker Expects its FluoroType® SARS-CoV-2 varID Q PCR Assay to Reliably Detect and Tentatively Differentiate Omicron (B.1.1.529) Variant
Kontron Introduces MediClient - A New Medical All-in-One Panel PC
Bruker Launches IconIR Nanoscale IR Spectroscopy Platform
Artificial Intelligence to Boost the Global Wound Care Market by 2026 with Minimal Intervention Solutions Finds Frost & Sullivan
Imec Signs Licensing Agreement with miDiagnostics to Commercialize its Patented Technology for Fast and Reliable COVID-19 Diagnosis
Withings Announces the FDA Clearance of ScanWatch its Most Medically Advanced Hybrid Smartwatch
Bruker Launches the Q4 POLO - Compact Spark-OES Metals Analyzer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2022 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today